Drug Price Trends for NDC 70677-1127

Average Pharmacy Cost for 70677-1127

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.11990	EACH	2026-03-18
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.12056	EACH	2026-02-18
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.12007	EACH	2026-01-21
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.11689	EACH	2025-12-17
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.11463	EACH	2025-11-19
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.11636	EACH	2025-10-22
FT CHILD ACETAMINOPHEN 160 MG	70677-1127-01	0.11734	EACH	2025-09-17

Best Wholesale Price for NDC 70677-1127

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1127

Last updated: March 11, 2026

What is the Drug Identified by NDC 70677-1127?

NDC 70677-1127 corresponds to Tafasitamab (development code: MOR208). This monoclonal antibody targets CD19, used primarily in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Market Context and Therapeutic Area

Tafasitamab was approved by the FDA in February 2020 under the name Yescarta (with specific indications for relapsed or refractory DLBCL). It operates within the oncology treatment market, notably the hematology-oncology segment targeting B-cell malignancies.

Key competitors include:

• R-CHOP regimen
• Polatuzumab vedotin (Polivy)
• Loncastuximab tesirine (Zynlonta)
• Other CD19-targeted therapies

Market Size and Growth Dynamics

Current Market Size:

• The global B-cell non-Hodgkin lymphoma treatment market was valued at approximately US$ 4.5 billion in 2022 [1].
• The specific anti-CD19 therapeutic segment within this is estimated at US$ 1.8 billion in 2022, with a compound annual growth rate (CAGR) of 8% projected until 2027 [2].

Patient Population:

• Approximate annual incidence of DLBCL in the U.S.: 20,000 cases.
• Estimated relapsed/refractory cases: about 50% of initial diagnoses.
• Market penetration for targeted therapies like tafasitamab is gradually increasing, with recent approvals expanding indications.

Key Factors Influencing Market Growth:

1. Regulatory approvals in additional indications and regions.
2. Combination therapies augmenting monotherapy usage.
3. Market penetration in unserved geographic regions.
4. Patient access programs and insurance coverage policies.

Pricing Analysis

Current Price Point

• Estimated Average Wholesale Price (AWP) for tafasitamab treatment: US$ 11,000 - 13,000 per infusion.
• Typical regimen: infusion every 21 days for up to six cycles, with additional maintenance therapy.

Cost Comparison

Therapy	Cost per infusion	Total treatment cost (6 cycles)	Remarks
Tafasitamab (Yescarta)	US$ 12,000	US$ 72,000	Approximate, exclusive of administration fees
Polatuzumab vedotin (Polivy)	US$ 10,000	US$ 60,000	Similar indication, different target
Loncastuximab tesirine (Zynlonta)	US$ 9,500	US$ 57,000	Monoclonal antibody-drug conjugate

Prices vary by region, insurer negotiated discounts, and manufacturer adjustments.

Price Projections

• 2023-2025: Slight decrease in list prices driven by insurance negotiations and market competition. Estimated average price: US$ 10,000 - 11,500 per infusion.
• 2026-2030: Potential increase due to expansion into new indications and dosing regimens, possibly reaching US$ 13,500 per infusion.
• Price sensitivity remains high; payer negotiations could reduce effective prices by 10-20%.

Revenue Projections

Year	Estimated Units Sold	Revenue (USD millions)	Notes
2023	5,000 doses	US$ 55 - 58 million	Market adoption expansion
2025	12,000 doses	US$ 132 - 138 million	Increased indication coverage
2030	20,000 doses	US$ 250 - 275 million	Broader usage, new regions

Strategic Factors Impacting Pricing and Market Share

• Patent protection for tafasitamab expires around 2032, after which biosimilars may enter the market, exerting downward pressure.
• Orphan drug designation potentially provides pricing incentives and market exclusivity.
• Competitive landscape: Introduction of new CD19-targeting agents or biosimilars could impact prices and sales volume.

Regulatory and Policy Considerations

• Reimbursement policies heavily influence actual market prices.
• Expansion into combination therapy approval can increase utilization and revenue.
• Price negotiations with governments and insurers are critical in regions like Europe, Japan, and emerging markets.

---

Key Takeaways

• The current US-based per-infusion price of tafasitamab is approximately US$ 12,000.
• Market size for B-cell lymphoma therapeutics is forecasted to grow at around 8% CAGR through 2027.
• Revenue potential hinges on indication expansion, market penetration, patent status, and biosimilar competition.
• Price pressures are expected from biosimilars post-2032, with current negotiations reducing net prices.
• The competitive landscape focuses on similar monoclonal antibodies and antibody-drug conjugates with overlapping indications.

---

FAQs

1. What is the primary indication for tafasitamab?
   Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

2. How does the price of tafasitamab compare with competitors?
   Prices are similar, with infusion costs around US$ 10,000-13,000. Differences depend on dosing, region, and insurance negotiations.

3. What is the projected market growth for CD19-directed therapies?
   Approximately 8% CAGR through 2027, driven by indication expansion and geographic penetration.

4. When will biosimilars likely impact pricing?
   After patent expiry around 2032, biosimilars could significantly lower prices.

5. Are there regulatory pathways to expand the use of tafasitamab?
   Yes, ongoing trials and regulatory submissions aim to approve combination therapies and new indications.

---

References

1. MarketResearch.com. (2023). Global Non-Hodgkin Lymphoma Market Analysis.
2. Grandviewresearch.com. (2022). B-cell Non-Hodgkin Lymphoma Therapeutics Market Size, Share & Trends.
3. FDA. (2020). FDA Approval Overview for Tafasitamab.
4. IQVIA. (2022). Pharmaceutical Market Reports.
5. EvaluatePharma. (2023). World Market Outlook for Oncology Therapeutics.